The company, created by the merger of Glaxo Wellcome and SmithKline Beecham late last year, is believed to have set a savings target of £850 million over the next three years, of which two-thirds will come from procurement. Purchasing chiefs are set to meet key suppliers at the beginning of April to discuss future strategy, including possible supplier rationalisation...